In a historic moment for gene editing, the U.S. late last year approved Casgevy, the first CRISPR-based therapy for sickle cell disease and beta thalassemia. One of the key figures behind the news was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results